

**APPENDIX – Listing of Claims from Amendment and Response to  
Restriction Requirement dated December 4, 2007**

Claims 1-24 (canceled)

Claim 25 (previously presented): A method of treating humans suffering from rheumatoid arthritis which comprises administering to said human in need of such a treatment a dose of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof.

Claim 26 (previously presented): The method according to claim 25 wherein the compound of formula I is in the form of the monomethanesulfonate salt.

Claim 27 (previously presented): The method according to claim 26 wherein the monomethanesulfonate salt of the compound of formula I is administered at a daily dose corresponding to 100 to 1000 mg of the compound of formula I free base.

Claim 28 (previously presented): The method according to claim 27 wherein the daily dose corresponds to 200 to 800 mg of the compound of formula I free base.

Claim 29 (previously presented): The method for according to claim 25 wherein the administration is once daily for a period exceeding 3 months.

Claim 30-39 (canceled)